Arcturus Therapeutics To Present At Canaccord Annual Growth Conference August 11
Arcturus Therapeutics Holdings Inc ARCT
$5.76
▼ -2.70%
($-0.16)
🔥 High Short Interest
🎢 High Beta
📅 Earnings This Week
Open
$5.94
Prev Close
$5.92
Day Range
$5.64 – $5.96
52W Range
$5.50 – $24.17
Market Cap
$163.72M
Beta
2.28
EPS (TTM)
$-2.82
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-05-22 |
| Shares Out. | 28,420,000 |
| Website | arcturusrx.com/ ↗ |
| Phone | 18589002660 |
| Employees | 111 |
| Revenue | $2.1M |
| Gross Profit | $2.1M |
| Net Income | -$27.0M |
| Free Cash Flow | -$58.7M |
| Total Assets | $245.4M |
| Total Liabilities | $54.0M |
| Equity | $191.4M |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Arcturus Therapeutics Holdings Inc is a publicly traded company under the ticker symbol ARCT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)